Adaptive Biotechnologies vs Ligand Pharmaceuticals
Adaptive Biotechnologies reported revenue of $277 million in fiscal 2025, about the same as Ligand Pharmaceuticals' $268 million in fiscal 2025. Adaptive Biotechnologies' revenue grew 54.8% in its latest year, and Ligand Pharmaceuticals' grew 60.4%. Adaptive Biotechnologies had an operating margin of -20.6%, against 15.3% at Ligand Pharmaceuticals. Free cash flow was −$49 million at Adaptive Biotechnologies and $49 million at Ligand Pharmaceuticals.
Side by side
| Adaptive Biotechnologies | Ligand Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $277M | $268M |
| Revenue growth | 54.8% | 60.4% |
| Revenue growth a year, last 5 years | 23.0% | 10.4% |
| Gross margin | 74.2% | — |
| Operating margin | −20.6% | 15.3% |
| Net margin | −21.5% | 46.4% |
| Free cash flow | −$49M | $49M |
| Free cash flow margin | −17.7% | 18.2% |
| Return on capital | −37.2% | 4.9% |
| Net debt to EBITDA | — | −3.8x |
| Dividends and buybacks | $0M | $15M |
| Change in diluted share count | 3.1% | 11.0% |
| Last close | $29.04 | $308.79 |
| P/E at the last close | — | 134.3× |
| Insider trades, last 12 months | sold $121.6 million | sold $34.2 million |
| Piotroski F-score | 5 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Adaptive BiotechnologiesLigand Pharmaceuticals
Operating margin
Percent of revenue
Adaptive BiotechnologiesLigand Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Adaptive BiotechnologiesLigand Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Adaptive Biotechnologies and Ligand Pharmaceuticals pages.